Novel genetic targets in endometrial cancer

Abstract

Worldwide, ∼ 74,000 women die from endometrial cancer each year. Understanding the somatic genomic alterations that drive endometrial tumorigenesis may provide new opportunities to identify targeted therapies for specific subsets of patients. Since 2012, the use of next-generation sequencing to decode the mutational landscape of endometrial tumors has not only confirmed prior knowledge of established genetic targets for serous and endometrioid endometrial carcinomas (ECs), but has also uncovered novel significantly mutated genes, referred to herein as novel genetic targets, which represent candidate cancer genes in these tumors. This editorial summarizes the novel genetic targets that have been identified in serous and endometrioid ECs, according to their unifying functional characteristics. An expert opinion section comments on remaining knowledge gaps that will undoubtedly be filled in future genomic studies of endometrial cancer.

Keywords::

• endometrial
• gene
• mutation
• uterine

1. Introduction

Most endometrial cancers are endometrial carcinomas (ECs), which are further classified into numerous histopathological subtypes including endometrioid and serous ECs [1]. Endometrioid tumors account for ∼ 80% of newly diagnosed ECs. Although they have a good overall prognosis, improved therapeutic strategies are needed to treat recurrent and advanced-stage endometrioid tumors. Likewise, alternative therapeutic approaches are needed for the treatment of serous ECs, which have a poor overall prognosis. In the era of precision medicine, comprehensive interrogations of tumor exomes and genomes for somatic alterations have been driven by the hope that they will reveal novel genetic targets that might ultimately guide treatment. For the purposes of this editorial, the consideration of novel genetic targets is limited to mutated genes; other classes of genomic and epigenomic alterations also represent novel genetic targets but are beyond the scope of this discussion.

2. Novel genetic targets in endometrioid and serous ECs

Recent massively parallel sequencing of endometrioid and serous ECs by individual laboratories [2-6], and by The Cancer Genome Atlas (TCGA) [7], has uncovered novel, statistically significantly mutated genes (SMGs) in these tumors, that is, genes that are mutated at a statistically significantly higher rate than background and which therefore represent candidate cancer genes. Furthermore, the integrated genomic analysis of endometrioid and serous ECs by TCGA revealed that they can be reclassified into four distinct molecular subgroups: ultramutated/POLE mutant, hypermutated/microsatellite instability (MSI), copy number low/microsatellite stable (MSS) and copy number high/serous-like [7]. The abundance of SMGs in the ultramutated subgroup precludes their discussion in this editorial. Among the remaining 3 subgroups, 32 SMGs, including 20 novel genetic targets (Table 1), have been described [7]. For ease of discussion herein, these novel genetic targets are loosely categorized according to their major ascribed functions.

Table 1. Mutation frequency of novel significantly mutated protein-encoding genes identified among serous and non-ultramutated endometrioid ECs.

Gene symbol	Frequency of somatic mutations*						Ref.
	Histological subtype		Molecular subgroup [7]
	Endometrioid (%)	Serous (%)	Ultramutated (%)	Hypermutated/MSI (%)	Copy number low/MSS (%)	Copy number high/serous-like (%)
ARID5B	9 – 18	0	47	23	6	0	[6,7]
BCOR	4 – 10	0	65	17	7	0	[6,7]
CHD4	7 – 13	13 – 18	65	6	12	13	[3,4,6,7]
CSDE1	7	0	59	15	1	0	[7]
CTCF	15 – 29	0	41	23	21	0	[6,7,9]
FBXW7	7 – 27	20 – 29	82	9	6	22	[2-4,6,7]
GIGYF2	8 – 14	6	59	20	0	7	[6,7]
HIST1H2BD	2	0	0	8	1	0	[7]
LIMCH1	6 – 9	0	53	12	0	0	[6,7]
MECOM	4	0	24	5	4	0	[7]
METTL14	3	0	24	5	3	0	[7]
NKAP	4	0	18	11	1	0	[6,7]
RBMX	4	0	24	12	0	0	[7]
RPL22	10 – 52	0	29	37	0	0	[7,21]
SGK1	4	2	35	3	6	2	[7]
SOX17	2	0	0	0	8	0	[7]
SPOP	0 – 6	4 – 8	29	6	10	5	[3,4,6,7]
TAF1	11 – 27	4 – 9	82	25	1	5	[4,6,7]
TNFAIP6	2	0	29	2	1	0	[7]
ZFHX3	13 – 36	6	82	31	2	7	[6,7]

CSMD3 is a novel SMG in EC but is not shown in Table 1 because it may be a false-positive.

MIR1277 is significantly mutated but is not shown in Table 1 because it is not a protein-encoding gene.

*Mutation frequencies for the TCGA dataset were obtained from Kandoth et al. [7] and via the cBioPortal for Cancer Genomics [32,33].

MSI: Microsatellite instability; MSS: Microsatellite stable; SMG: Significantly mutated gene; TCGA: The Cancer Genome Atlas.

2.1 Transcriptional regulation

Six novel SMGs, CTCF, ZFHX3 (Zinc finger homeobox 3), SOX17, BCOR, MECOM and TAF1, encode transcriptional regulators. CTCF (CCCTC-binding factor) encodes a zinc-finger transcription factor that regulates transcriptional activation and repression, and influences chromatin architecture [8]. Frequent truncating mutations within CTCF in MSI+ endometrioid ECs, and the unstable nature of the truncated transcripts, have led to the proposal that CTCF may be a haploinsufficient tumor suppressor gene in these tumors [9]. Another transcription factor gene, ZFHX3, is significantly mutated in hypermutated/MSI ECs [7]. ZFHX3 is a putative tumor suppressor gene based on its location within a common region of 16q22 deletion in human cancer and the occurrence of frequent somatic mutations in prostate cancer [10]. SOX17 (SRY [sex determining region Y]-box 17), an SMG in copy number low/MSS ECs, encodes an high mobility group box transcription factor that, among other effects, negatively regulates WNT/β-catenin signaling [11]. In copy number low/MSS ECs, SOX17 mutations are mutually exclusive with other genetic aberrations affecting the WNT/β-catenin pathway, suggesting that they likely perturb WNT signaling [7]. BCOR (BCL6 corepressor), which encodes a corepressor of BCL6, is significantly mutated in copy number low/MSS ECs [7]. MECOM (MDS1 and EVI1 complex locus), a protooncogene that encodes a zinc-finger transcription factor, is significantly mutated in copy number low/MSS ECs [7]. Although the functional impact of MECOM mutations in EC is unknown, it is noteworthy that MECOM inhibitors are being developed [12]. Finally, TAF1 (TAF1 RNA polymerase II, TATA box binding protein-associated factor, 250 kDa) encodes a subunit of the TFIID basal transcription factor and is an SMG in serous EC [4].

2.2 Chromatin remodeling and chromatin organization

CHD4 (chromodomain helicase DNA binding protein 4) and ARID5B (AT-rich interactive domain 5B [MRF1-like]) are novel SMGs involved in chromatin remodeling [3,7]. CHD4 was first implicated in EC by virtue of its designation as an SMG in serous tumors [3]. CHD4 is a subunit of the NuRD complex, which is a transcriptional activator and repressor, and is implicated in the DNA damage response [13]. ARID5B (AT-rich interactive domain 5B [MRF1-like]) is an SMG in hypermutated/MSI ECs and encodes a DNA-binding protein that complexes with PHF2 (PHD finger protein 2), a lysine demethylase. The DNA-binding activity of ARID5B is believed to direct the ARID5B–PHF2 complex to specific gene promoters resulting in histone demethylation and transcriptional activation [14]. Another SMG in hypermutated/MSI ECs is HIST1H2BD (histone cluster 1, H2bd), which encodes a core component of the nucleosome.

2.3 Ubiquitin-mediated protein degradation

FBXW7 (F-Box and WD repeat domain containing 7, E3 ubiquitin protein ligase) and SPOP (speckle-type POZ protein), which encode the substrate recognition components of the SKP1-CUL1-FBXW7 and SPOP-CUL3 ubiquitin ligase complexes, respectively, are SMGs in serous ECs [2-4]. FBXW7 is a bona fide tumor suppressor and SPOP is a putative tumor suppressor. Many of the FBXW7 mutations documented in EC encode dominant-negative or loss-of -function mutants in other tumor types and it is therefore anticipated that SPOP mutations in EC may function similarly [3]. In certain cellular contexts, loss of FBXW7 function is associated with in vitro sensitivity to sorafenib and resistance to antitubulin chemotherapeutics [15], or sensitivity to an histone deacetylase inhibitor [16]. However, the relevance of those observations to FBXW7-mutant endometrial cancers remains to be elucidated.

2.4 RNA binding or RNA modification

Four novel genetic targets, RPL22, RBMX, CSDE1 and METTL14, have RNA-binding capability or RNA modification activity. RPL22 (ribosomal protein L22) encodes a ribosomal protein and is believed to be a tumor suppressor gene in T-ALL [17]. RPL22 mutations are extraordinarily frequent (52%) in MSI+ EECs, and are attributed to a recurrent frameshift mutation (c.43delA) suggesting loss of function [18]. RBMX (RNA-binding motif protein, X-linked) encodes an RNA-binding protein that regulates pre-mRNA splicing [19], and is implicated in the DNA damage response [20], mitotic sister chromatid cohesion [21] and the regulation of tumor necrosis factor receptor 1 release. RBMX is an SMG in hypermutated/MSI ECs, exhibiting recurrent in-frame deletions encompassing the translation start site. CSDE1 (cold shock domain containing E1, RNA-binding), an SMG in hypermutated/MSI EC, encodes an RNA- and single-stranded DNA-binding protein that regulates mRNA turnover and translation [22]. Most CSDE1 mutations in EC are missense mutations, including three recurrently mutated residues (R174, R726, R774). Finally, METTL14 (methyltransferase like 14) is significantly mutated in hypermutated/MSI ECs [7], and encodes a methyltransferase that complexes with METTL3 and methylates m⁶A on nuclear RNA [23]. The majority of METTL14 mutations in EC are missense mutations within the methyltransferase domain, including a recurrent R298P mutation [7].

2.5 Other functions

NKAP, GIGYF2, LIMCH1, TNFAIP6 and SGK1 are novel genetic targets that do not precisely fit into the previously discussed categories. NKAP (NFKB-activating protein) regulates NF kappa B activation induced by TNF and IL-1 [24], is a transcriptional corepressor for Notch [25] and has been implicated in RNA splicing [26]. NKAP is significantly mutated in hypermutated/MSI ECs [7]. GIGYF2 (GRB10 interacting GYF protein 2), encoded by an SMG in hypermutated/MSI ECs, is involved in IGF-I receptor signaling [27], and is implicated in the regulation of protein translation [28]. LIMCH1 (LIM and Calponin homology domains 1) encodes a protein with a poorly defined function and is significantly mutated in hypermutated/MSI ECs [7]. The R421fs frameshift mutation accounts for almost all LIMCH1 mutations in hypermutated/MSI ECs and is predicted to encode a truncated protein lacking the LIM domain. TNFAIP6 (TNFα-induced protein 6) is significantly mutated in hypermutated/MSI ECs. The encoded protein interacts with components of the extracellular matrix including hyaluronan [29], and is involved in the inflammatory response and tissue remodeling [30]. Finally, SGK1 (serum/glucocorticoid regulated kinase 1), an SMG in copy number low/MSS ECs, encodes a kinase implicated in the regulation of a wide range of cellular processes including tumor cell survival. Although SGK1 has received attention as a potential druggable target in cancer [31], the biological and therapeutic relevance of SGK1 mutations in EC remains unknown.

3. Mutation patterns between SMGs

Patterns of mutations between genes can provide insights into their possible functional effects. Here, the pattern of mutations among the 32 SMGs, identified in non-ultramutated ECs in TCGA, was obtained via the cBioPortal for Cancer Genomics (Supplementary Tables 1 – 4) [32,33]. As shown in Table 2, mutations in a number of novel SMGs showed a tendency for mutually exclusive or co-occurring mutations, suggesting, respectively, possible functional redundancy or cooperativity.

Table 2. Statistically significant trends in mutation patterns* involving novel SMGs identified in non-ultramutated ECs in the TCGA study [7].

Molecular subgroup	Gene pair	Trend in mutation pattern*	p-value*
Hypermutated/MSI	ARID5B-ZFHX3	Co-occurrence	0.035
	CTCF-FGFR2	Co-occurrence	0.025
	FBXW7-LIMCH1	Co-occurrence	0.021
	BCOR- PPP2R1A	Co-occurrence	0.006
	HIST1H2BD -RPL22	Co-occurrence	0.005
	SPOP-RPL22	Co-occurrence	0.016
	SPOP-CCND1	Co-occurrence	0.005
	SPOP-PPP2R1A	Co-occurrence	0.040
	MECOM-PPP2R1A	Co-occurrence	0.021
	MECOM-ATR	Co-occurrence	0.0004
	METTL14-FGFR2	Co-occurrence	0.048
	METTL14-PPP2R1A	Co-occurrence	0.021
	SGK1-RBMX	Co-occurrence	0.013
	TNFAIP6-MECOM	Co-occurrence	0.046
	TNFAIP6-METTL14	Co-occurrence	0.046
Copy number low/MSS	SPOP-PTEN	Mutual exclusivity	0.029
	SOX17-CTNNB1	Mutual exclusivity	0.043
	FBXW7-CTNNB1	Mutual exclusivity	0.022
	FBXW7-SOX17	Co-occurrence	0.047
	MECOM-PIK3R1	Co-occurrence	0.011
Copy number high/serous-like	CHD4-FBXW7	Co-occurrence	0.009
	GIGYF2-TP53	Mutual exclusivity	0.001
Ultramutated	ZFHX3-PIK3CA	Co-occurrence	0.015
	ZFHX3-ATR	Co-occurrence	0.029
	GIGYF2-CSDE1	Co-occurrence	0.004
	SGK1-CTNNB1	Co-occurrence	0.017
	ATR-CTNNB1	Co-occurrence	0.017
	CSDE1-FGFR2	Co-occurrence	0.041
	GIGYF2-FGFR2	Co-occurrence	0.041
	LIMCH1-PPP2R1A	Co-occurrence	0.020
	SPOP-KRAS	Mutual exclusivity	0.009
	RBMX-KRAS	Mutual exclusivity	0.029
	CCND1-RPL22	Co-occurrence	0.014

SMGs identified in the ultramutated subgroup were not included in the input query. Only gene-pairs demonstrating a p-value < 0.05, as derived via Fisher's exact test, are shown; p-values are not adjusted for false discovery rate.

*Data were obtained from the cBioCancer Genomics Portal [32,33].

MSI: Microsatellite instability; MSS: Microsatellite stable; SMGs: Significantly mutated genes; TCGA: The Cancer Genome Atlas.

4. Expert opinion

With novel genetic targets for serous and endometrioid EC now in hand, the challenge will be to determine whether any of these targets are therapeutically relevant. This can take the form of biochemical and biological studies of mutant proteins in their proper cellular and genetic context, systems biology approaches to functionalize the genome [5], as well as systematic searches for gene–drug interactions. One strategy to prioritize genetic targets for further analysis is to focus on the most frequently mutated of the SMGs, which, if proven to be druggable, would theoretically maximize the number of patients who might gain clinical benefit. Alternatively, SMGs that have reported gene–drug interactions and/or are being evaluated as druggable targets in preclinical studies within other cellular contexts, such as FBXW7, MECOM and SGK1, could be prioritized for assessment of their therapeutic relevance to EC. In terms of seeking druggable targets, it is noteworthy that catalogs of SMGs are dynamic rather than static and depend on the assumptions and parameters used in statistical calculations as well as user-defined statistical cutoffs. Moreover, current catalogs of genetic targets in serous and endometrioid ECs have principally been derived from analyses of primary tumor tissues resected prior to treatment. As such, there may be additional genetic targets yet to be discovered within recurrent or persistent tumors that are refractory to therapy, or in metastatic disease. Additionally, the genomic landscape of other histological subtypes of EC remains to be elucidated. Finally, it remains to be seen whether additional novel genetic targets will emerge from sequencing of larger numbers of tumors corresponding to each of the four recently defined molecular subgroups of serous and endometrioid EC.

Declaration of interest

D W Bell is a co-inventor on a patent describing EGFR mutations, which is licensed to Genzyme. The author is funded through the Intramural Research Program of the National Human Genome Research Institute at NIH. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.